Aktuellt
SENASTE
Redeye provides a research update following the Q2 report published by Initiator Pharma earlier today. Overall, the report did not contain any significant surprises and was in line with our expectations. However, we are encouraged by the progress made in clinical development by the company during the quarter. We reiterate our fair value range with a base case valuation of SEK16 as we look forward to the crucial phase IIb data readout from pudafensine expected later this year.
LÄS MER
